AbbVie AG - Rinvoq 15 mg, Retardtabletten | | 67257 | | 01 | | Rinvoq 15 mg | | Retardtabletten | | L04AF03 | | | | 20.01.2020 | | |
| Composition | upadacitinibum 15 mg ut upadacitinibum hemihydricum, cellulosum microcristallinum, hypromellosum, mannitolum, acidum tartaricum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, E 171, E 172 (nigrum), E 172 (rubrum), pro compresso obducto. | Packungsbestandteile | | Delayed release tablets | | | Active Agent | Dose |
---|
Upadacitinibum | 15 mg |
| BAG: Active Agent | Dose |
---|
Upadacitinibum | 15 mg |
| | Inactive agents | Dose | additional_information |
---|
(Nigrum) | | | (Rubrum) | | | Tartaric Acid | | | Cellulosum Microcristallinum | | | E 171 | | color. | E 172 | | color. | Hypromellosum | | | Macrogol | 3350 | | Magnesii Stearas | | | Mannitol | | | Poly(Alcohol Vinylicus) | | Überzug | Pro Compresso Obducto | | | Silica Colloidalis Anhydrica | | | Talcum | | |
| |
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
---|
001 | 28 | 765.24 | 848.65 | B | SL | Yes |
|
|